Prolonged recovery rate of CB1 receptor adaptation after cessation of long-term cannabinoid administration

Molecular Pharmacology

Volumn 70, Issue 3, 2006, Pages 986-996

  Sim Selley, Laura J ^a   Schechter, Nicole S ^a   Rorrer, W Kirk ^a   Dalton, George D ^a   Hernandez, Jerry ^a   Martin, Billy R ^a   Selley, Dana E ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; CANNABINOID; CANNABINOID 1 RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; GUANINE NUCLEOTIDE BINDING PROTEIN GAMMA SUBUNIT; RECEPTOR PROTEIN; RIMONABANT; TETRAHYDROCANNABINOL;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING SITE; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; CORPUS STRIATUM; DATA ANALYSIS; HIPPOCAMPUS; IMMUNOBLOTTING; MOUSE; NONHUMAN; NORTHERN BLOTTING; PRIORITY JOURNAL; RECEPTOR BINDING; RECEPTOR DOWN REGULATION; TRANSCRIPTION REGULATION;

ADAPTATION, PHYSIOLOGICAL; ANIMALS; BINDING SITES; CANNABINOIDS; CORPUS STRIATUM; GENE EXPRESSION REGULATION; GTP-BINDING PROTEINS; HIPPOCAMPUS; MALE; MICE; RECEPTOR, CANNABINOID, CB1; RNA, MESSENGER; TIME FACTORS;

EID: 33747626926     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.105.019612     Document Type: Article

References (41)

1. Aceto MD, Scates SM, Lowe JA, and Martin BR (1995) Cannabinoid precipitated withdrawal by the selective cannabinoid receptor antagonist, SR 141716A. Eur J Pharmacol 282:R1-R2.
2. Andersson H, D'Antona AM, Kendall DA, VonHeijne G, and Chin CN (2003) Membrane assembly of the cannabinoid receptor 1: impact of a long N-terminal tail. Mol Pharmacol 64:570-577.
3. Bass CE and Martin BR (2000) Time course for the induction and maintenance of tolerance to Delta(9)-tetrahydrocannabinol in mice. Drug Alcohol Depend 60:113-119.
4. Bodor AL, Katona I, Nyiri G, Mackie K, Ledent C, Hajos N, and Freund TF (2005) Endocannabinoid signaling in rat somatosensory cortex: laminar differences and involvement of specific interneuron types. J Neurosci 25:6845-6856.
5. 9-tetrahydrocannabinol treatment produces a time-dependent loss of cannabinoid receptor-activated G-proteins in brain. J Neurochem 73:2447-2459.
6. Carlini EA (1968) Tolerance to chronic administration of cannabis sativa (marihuana) in rats. Pharmacology 1:135-142.
7. Chan GC, Hinds TR, Impey S, and Storm DR (1998) Hippocampal neurotoxicity of delta9-tetrahydrocannabinol. J Neurosci 18:5322-5332.
8. 9-tetrahydrocannabinol and morphine. J Pharmacol Exp Ther 297:121-127.
9. Compton DR, Rice KC, DeCosta BR, Razdan RK, Melvin LS, Johnson MR, and Martin BR (1993) Cannabinoid structure-activity relationships: correlation of receptor binding and in vivo activities. J Pharmacol Exp Ther 265:218-226.
10. Coutts AA, Anavi-Goffer S, Ross RA, MacEwan DJ, Mackie K, Pertwee RG, and Irving AJ (2001) Agonist-induced internalization and trafficking of cannabinoid CB1 receptors in hippocampal neurons. J Neurosci 21:2425-2433.
11. 9-THC following 35 days of exposure. Neurosci Res Commun 17:9-18.
12. Herkenham M, Lynn AB, Johnson MR, Melvin LS, de Costa BR, and Rice KC (1991) Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci 11:563-583.
13. Heyser CJ, Hampson RE, and Deadwyler SA (1993) Effects of delta-9-tetrahydrocannabinol on delayed match to sample performance in rats: alterations in short-term memory associated with changes in task specific firing of hippocampal cells. J Pharmacol Exp Ther 264:294-307.
14. Hollister LE (1986) Health aspects of cannabis. Pharmacol Rev 38:1-20.
15. i in the inhibition of adenylate cyclase by cannabimimetic drugs. Mol Pharmacol 29:307-313.
16. Hsieh C, Brown S, Derleth C, and Mackie K (1999) Internalization and recycling of the CB1 cannabinoid receptor. J Neurochem 73:493-501.
17. Jin W, Brown S, Roche JP, Hsieh C, Celver JP, Kovoor A, Chavkin C, and Mackie K (1999) Distinct domains of the CB1 cannabinoid receptor mediate desensitization and internalization. J Neurosci 19:3773-3780.
18. Jones RT, Benowitz NL, and Herning RI (1981) Clinical relevance of cannabis tolerance and dependence. J Clin Pharmacol 21:143S-152S.
19. Landfield PW, Cadwallader LB, and Vinsant S (1988) Quantitative changes in hippocampal structure following long-term exposure to delta 9-tetrahydrocannabinol: possible mediation by glucocorticoid systems. Brain Res 443:47-62.
20. Ledent C, Valverde O, Cossu G, Petitet F, Aubert JF, Beslot F, Bohme GA, Imperato A, Pedrazzini T, Roques BP, et al. (1999) Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science (Wash DC) 283:401-404.
21. Mackie K, Lai Y, Westenbroek R, and Mitchell R (1995) Cannabinoids activate an inwardly rectifying potassium conductance and inhibit Q-type calcium currents in AtT20 cells transfected with rat brain cannabinoid receptor. J Neurosci 15:6552-6561.
22. Martin BR, Sim-Selley LJ, and Selley DE (2004) Signaling pathways involved in the development of cannabinoid tolerance. Trends Pharmacol 25:325-330.
23. McIntosh HH, Song C, and Howlett AC (1998) CB1 cannabinoid receptor: cellular regulation and distribution in N18TG2 neuroblastoma cells. Brain Res Mol Brain Res 53:163-173.
24. McLaughlin CR and Abood ME (1993) Developmental expression of cannabinoid receptor mRNA. Dev Brain Res 76:75-78.
25. Rinaldi-Carmona M, Le Duigou A, Oustric D, Barth F, Bouaboula M, Carayon P, Casellas P, and Le Fur G (1998) Modulation of CB1 cannabinoid receptor functions after a long-term exposure to agonist or inverse agonist in the Chinese hamster ovary cell expression system. J Pharmacol Exp Ther 287:1038-1047.
26. 9- tetrahydrocannabinol on cannabinoid receptor binding and mRNA levels in several rat brain regions. Mol Brain Res 46:100-108.
27. Rubino T, Massi P, Patrini G, Venier I, Giagnoni G, and Parolaro D (1994) Chronic CP-55,940 alters cannabinoid receptor mRNA in the rat brain: an in situ hybridization study. Neuroreport 5:2493-2496.
28. Ryberg E, Vu HK, Larsson N, Groblewski T, Hjorth S, Elebring T, Sjogren S, and Greasley PJ (2005) Identification and characterisation of a novel splice variant of the human CB1 receptor. FEBS Lett 579:259-264.
29. B-mediated inhibition of adenylyl cyclase in mouse cerebellum. Mol Pharmacol 66:1275-1284.
30. Shapira M, Gafni M, and Sarne Y (2003) Long-term interactions between opioid and cannabinoid agonists at the cellular level: cross desensitization and downregulation. Brain Res 960:190-200.
31. Shire D, Carillon C, Kaghad M, Calandra B, Rinaldi-Carmona M, Le Fur G, Caput D, and Ferrara P (1995) An amino-terminal variant of the central cannabinoid receptor resulting from alternative splicing. J Biol Chem 270:3726-3731.
32. 35S]GTPγS autoradiography in rat brain. J Neurosci 16:8057-8066.
33. Sim-Selley LJ (2003) Regulation of cannabinoid CB1 receptors in the central nervous system by chronic cannabinoids. Crit Rev Neurobiol 15:91-119.
34. 9-tetrahydrocannabinol on cannabinoid receptor adaptation in mice. J Pharmacol Exp Ther 303:36-44.
35. Tsou K, Brown S, Sanudo-Pena MC, Mackie K, and Walker JM (1998) Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience 83:393-411.
36. Tsou K, Patrick SL, and Walker JM (1995) Physical withdrawal in rats tolerant to Δ9-tetrahydrocannabinol precipitated by a cannabinoid receptor antagonist. Eur J Pharmacol 280:R13-R15.
37. Twitchell W, Brown S, and Mackie K (1997) Cannabinoids inhibit N- and P/Q-type channels in cultured rat hippocampal neurons. J Neurophysiol 78:43-50.
38. Varvel SA and Lichtman AH (2002) Evaluation of CB1 receptor knockout mice in the Morris water maze. J Pharmacol Exp Ther 301:915-924.
39. Whitlow CT, Freedland CS, and Porrino LJ (2002) Metabolic mapping of the time-dependent effects of delta 9-tetrahydrocannabinol administration in the rat. Psychopharmacology (Berl) 161:129-136.
40. 9-THC on expression of cannabinoid receptor (CB1) mRNA in different rat brain regions. Mol Brain Res 62:141-149.
41. Zimmer A, Zimmer AM, Hohmann AG, Herkenham M, and Bonner TI (1999) Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice. Proc Natl Acad Sci USA 96:5780-5785.